CELLECTIS S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.345 EUR | -1.47% |
|
-1.88% | -15.16% |
| Sales 2023 * | 21.51M 23M 1.84B | Sales 2024 * | 27.32M 29.21M 2.34B | Capitalization | 168M 180M 14.41B |
|---|---|---|---|---|---|
| Net income 2023 * | -69M -73.78M -5.91B | Net income 2024 * | -69M -73.78M -5.91B | EV / Sales 2023 * | 4.36 x |
| Net cash position 2023 * | 74.53M 79.69M 6.38B | Net cash position 2024 * | 18.69M 19.98M 1.6B | EV / Sales 2024 * | 5.48 x |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 234 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cellectis S.A.
More recommendations
More press releases
More news
| 1 day | -1.47% | ||
| 1 week | -1.88% | ||
| Current month | -5.75% | ||
| 1 month | +2.85% | ||
| 3 months | -11.51% | ||
| 6 months | +157.41% | ||
| Current year | -15.16% |
1 week
2.32
2.50
1 month
2.272.74
Current year
2.132.88
1 year
0.893.44
3 years
0.8916.87
5 years
0.8928.45
10 years
0.8941.95
| Managers | Title | Age | Since |
|---|---|---|---|
David Sourdive
FOU | Founder | 57 | 19/12/99 |
André Choulika
FOU | Founder | 59 | 19/12/99 |
Bing C. Wang
DFI | Director of Finance/CFO | 47 | 09/02/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 04/11/20 | |
André Choulika
FOU | Founder | 59 | 19/12/99 |
David Sourdive
FOU | Founder | 57 | 19/12/99 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 2.345 | -1.47% | 45,065 |
| 25/04/24 | 2.38 | -1.04% | 18,491 |
| 24/04/24 | 2.405 | -0.62% | 19,554 |
| 23/04/24 | 2.42 | -1.43% | 55,187 |
| 22/04/24 | 2.455 | +2.72% | 43,945 |
Real-time Euronext Paris, April 26, 2024 at 04:35 pm
More quotes
Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR-T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR-T cells for the treatment of cancer patients, and a platform for performing therapeutic genetic modifications in hematopoietic stem cells in a various diseases. Capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and its pioneering PulseAgile electroporation technology, Cellectis S.A. is developing innovative product candidates using the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis S.A. is developing UCART product candidates directed at the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells for the treatment of blood disorders, immune deficiencies, and lysosomal storage diseases.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.16% | 180M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ALCLS Stock
